

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number

WO 2025/006680 A8

(43) International Publication Date
02 January 2025 (02.01.2025)

(51) International Patent Classification:

A61K 31/519 (2006.01) A61P 7/00 (2006.01)
A61K 45/06 (2006.01)

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2024/035719

(22) International Filing Date:

27 June 2024 (27.06.2024)

Published:

— with international search report (Art. 21(3))

(25) Filing Language:

English

(26) Publication Language:

English

(48) Date of publication of this corrected version:

31 July 2025 (31.07.2025)

(30) Priority Data:

63/524,530	30 June 2023 (30.06.2023)	US
63/535,183	29 August 2023 (29.08.2023)	US
63/607,818	08 December 2023 (08.12.2023)	US
63/637,286	22 April 2024 (22.04.2024)	US

(15) Information about Correction:

see Notice of 31 July 2025 (31.07.2025)

(71) Applicant: **PRINCIPIA BIOPHARMA INC.** [US/US];
55 Corporate Drive, Bridgewater, New Jersey 08807 (US).

(72) Inventors: **DAAK, Ahmed**; c/o Sanofi, Patent Department,
450 Water Street, Cambridge, Massachusetts 02141 (US).
LEE, Michelle; c/o Sanofi, Patent Department, 450 Water
Street, Cambridge, Massachusetts 02141 (US). **GUO, Hail-
ing**; c/o Sanofi, Patent Department, 450 Water Street, Cam-
bridge, Massachusetts 02141 (US).

(74) Agent: **WINKLER, Lauren** et al.; 125 Cambridge Park
Drive, Suite 301, Cambridge, Massachusetts 02140 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: METHODS FOR TREATING PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA
IN CHILDREN, ADOLESCENTS AND ADULTS BY ADMINISTERING (R)-2-[3-[4-AMINO-3-(2-FLUO-
RO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-
METHYL-4-[4-(OXE-
TAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENITRILE

(57) Abstract: Methods for treating children, adolescents and adults with persistent or chronic immune thrombocytopenia comprising administering at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof are disclosed.



WO 2025/006680 A8